Delisting risk
HCWB · NASDAQ · Biotechnology

HCW Biologics (HCWB)

Develops fusion immunotherapies and cell-therapy manufacturing reagents.

$3.35
Pre-market+0.03 (+0.78%)
At close$3.32(−3.77%)

Something off on this page? Send us feedback.

Next report
Nov 12, 2026
estimated · in 70 days
EPS estimate
−$1.08
Revenue estimate
$118.7K
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$3.20−$0.05−$40.74−$4.13−$2.63$2.22−$11.58Pending
Estimate$3.60$10.80$1.58−$5.04−$2.64−$1.98−$1.08
Surprise−188.9%−477.2%−361.4%+47.8%+184.1%−484.8%

RevenueReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$394.8K$5.1K$1.3K$85.3K$27.0K$6.5M$135.6KPending
Estimate$7.0M$7.0M$7.0M$7.0M$6.5M$135.6K$118.7K
Surprise−94.4%−100.0%−98.8%−99.6%−0.2%0.0%

History

DateEstimateReportedSurprise
Nov 2026−$1.08
Aug 2026−$1.98−$11.58−484.8%
May 2026−$2.64$2.22+184.1%
Mar 2026−$5.04−$2.63+47.8%
Nov 2025$1.58−$4.13−361.4%

The latest year is open to everyone — the 24 quarters behind it read with an account.

Sign in
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Apr 2024
Mar 2024
Nov 2023
Aug 2023
May 2023
Mar 2023
Nov 2022
Aug 2022
May 2022
Mar 2022
Mar 2022
Nov 2021
Aug 2021
Mar 2021
Dec 2020
Sep 2020
Jun 2020
Mar 2020
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Nov 12, 2026−$1.08$118.7K
Aug 14, 2026−$1.98−$11.58−484.8%$135.6K$135.6K0.0%−8.5%
May 14, 2026−$2.64$2.22+184.1%$6.5M$6.5M−0.2%+262.4%
Mar 31, 2026−$5.04−$2.63+47.8%$7.0M$27.0K−99.6%−16.7%
Nov 14, 2025$1.58−$4.13−361.4%$7.0M$85.3K−98.8%+2.0%

The latest year is open to everyone — the 24 quarters behind it read with an account.

Sign in
Aug 18, 2025
May 15, 2025
Mar 28, 2025
Nov 14, 2024
Aug 14, 2024
May 15, 2024
Apr 1, 2024
Mar 26, 2024
Nov 14, 2023
Aug 11, 2023
May 9, 2023
Mar 28, 2023
Nov 7, 2022
Aug 12, 2022
May 13, 2022
Mar 29, 2022
Mar 28, 2022
Nov 12, 2021
Aug 13, 2021
Mar 31, 2021
Dec 31, 2020
Sep 30, 2020
Jun 30, 2020
Mar 31, 2020